CDKN2A and breast carcinoma: Changes in p16INK4a (p16) expression, a biomarker of aging, in peripheral blood T cells (PBTC) in patients receiving anthracycline (A) vs non-anthracycline (NoA) chemotherapy (CRx) for early stage breast cancer (EBC).